{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:33:20Z","timestamp":1780497200395,"version":"3.54.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2320-B-002-020-MY3"],"award-info":[{"award-number":["111-2320-B-002-020-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Part Fibre Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fine particulate matter 2.5 (PM\n                      <jats:sub>2.5<\/jats:sub>\n                      ), a key indicator of air pollution, is classified as a human carcinogen. However, the link between air pollution and bladder cancer (BC) progression remains unclear. Dysregulation of the Wingless-related integration site (Wnt)\/\u03b2-catenin and mitogen-activated protein kinase (MAPK)\/extracellular signal-regulated kinase (ERK) pathways is a key driver of tumorigenesis in multiple cancers, including BC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study demonstrated that PM\n                      <jats:sub>2.5<\/jats:sub>\n                      exposure enhances BC cell migration and invasion. Ribonucleic acid (RNA) sequencing identified the Wnt signaling pathway as a key regulator in PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -exposed BC cells. Elevated protein levels of Wnt3A, Wnt5A, and \u03b2-catenin, along with the nuclear translocation of \u03b2-catenin, further highlighted the role of the PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -activated Wnt\/\u03b2-catenin pathway in promoting BC progression. The interaction between the Wnt\/\u03b2-catenin and MAPK\/ ERK pathways was examined using inhibitors and shRNAs. MEK or ERK inhibition not only suppressed PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -induced upregulation of Wnt3A, Wnt5A, and \u03b2-catenin nuclear translocation but also significantly reduced the migration and invasion of PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -exposed BC cells. Both pathways represent promising therapeutic targets, and several existing pathway-specific inhibitors may be repurposed for the future clinical management of PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -induced BC progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      PM\n                      <jats:sub>2.5<\/jats:sub>\n                      promotes BC progression through both the MAPK\/ERK and Wnt\/\u03b2-catenin signaling pathways. MEK\/ERK inhibition suppressed PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -induced nuclear translocation of \u03b2-catenin, suggesting that the MAPK\/ERK pathway functions upstream of the Wnt\/\u03b2-catenin pathway. This study provides mechanistic insights into how PM\n                      <jats:sub>2.5<\/jats:sub>\n                      exposure drives BC progression and offers a potential foundation for developing targeted therapies for PM\n                      <jats:sub>2.5<\/jats:sub>\n                      -associated BC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12989-025-00656-3","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:37:26Z","timestamp":1768574246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK\/ERK and Wnt\/\u03b2-catenin pathways"],"prefix":"10.1186","volume":"23","author":[{"given":"Yung-Ting","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Hsi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ying","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Ni","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"10440","key":"656_CR1","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"Global burden and strength of evidence for","year":"2024","unstructured":"Global burden and strength of evidence for. 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2162\u2013203.","journal-title":"Lancet"},{"issue":"13","key":"656_CR2","doi-asserted-by":"crossref","first-page":"12648","DOI":"10.1007\/s11356-019-04874-z","volume":"26","author":"J Bazyar","year":"2019","unstructured":"Bazyar J, Pourvakhshoori N, Khankeh H, Farrokhi M, Delshad V, Rajabi E. A comprehensive evaluation of the association between ambient air pollution and adverse health outcomes of major organ systems: a systematic review with a worldwide approach. Environ Sci Pollut Res Int. 2019;26(13):12648\u201361.","journal-title":"Environ Sci Pollut Res Int"},{"key":"656_CR3","doi-asserted-by":"crossref","unstructured":"Zare Sakhvidi MJ, Lequy E, Goldberg M, Jacquemin B. Air pollution exposure and bladder, kidney and urinary tract cancer risk: A systematic review. Environmental pollution (Barking, Essex: 1987). 2020;267:115328.","DOI":"10.1016\/j.envpol.2020.115328"},{"key":"656_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.02.004","volume":"27","author":"YH Chuang","year":"2021","unstructured":"Chuang YH, Lin IF, Lao XQ, Lin C, Chan TC. The association between renal function decline and the incidence of urothelial carcinoma: A 16-year retrospective cohort study in Taiwan. Eur Urol Open Sci. 2021;27:1\u20139.","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"656_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"656_CR6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber I, Ong S, Bukavina L, Black PC, Comp\u00e9rat E, Kamat AM, et al. Epidemiology of bladder cancer in 2023: A systematic review of risk factors. Eur Urol. 2023;84(2):176\u201390.","journal-title":"Eur Urol"},{"issue":"5","key":"656_CR7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.euo.2020.02.004","volume":"4","author":"MA Bjurlin","year":"2021","unstructured":"Bjurlin MA, Matulewicz RS, Roberts TR, Dearing BA, Schatz D, Sherman S, et al. Carcinogen biomarkers in the urine of electronic cigarette users and implications for the development of bladder cancer: A systematic review. Eur Urol Oncol. 2021;4(5):766\u201383.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"656_CR8","first-page":"503","volume":"12","author":"PL Skipper","year":"2003","unstructured":"Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol. 2003;12(6):503\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"1","key":"656_CR9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/oem.2007.034348","volume":"65","author":"G Casta\u00f1o-Vinyals","year":"2008","unstructured":"Casta\u00f1o-Vinyals G, Cantor KP, Malats N, Tardon A, Garcia-Closas R, Serra C, et al. Air pollution and risk of urinary bladder cancer in a case-control study in Spain. Occup Environ Med. 2008;65(1):56\u201360.","journal-title":"Occup Environ Med"},{"key":"656_CR10","doi-asserted-by":"crossref","unstructured":"Li D, Li Y, Li G, Zhang Y, Li J, Chen H. Fluorescent reconstitution on deposition of PM\u2009<\u2009sub\u2009>\u20092.5\u2009in lung and extrapulmonary organs. Proceedings of the National Academy of Sciences. 2019;116(7):2488-93.","DOI":"10.1073\/pnas.1818134116"},{"key":"656_CR11","doi-asserted-by":"crossref","first-page":"104943","DOI":"10.1016\/j.envint.2019.104943","volume":"131","author":"S Chen","year":"2019","unstructured":"Chen S, Li D, Zhang H, Yu D, Chen R, Zhang B, et al. The development of a cell-based model for the assessment of carcinogenic potential upon long-term PM2.5 exposure. Environ Int. 2019;131:104943.","journal-title":"Environ Int"},{"key":"656_CR12","doi-asserted-by":"crossref","unstructured":"Santib\u00e1\u00f1ez-Andrade M, Chirino YI, Gonz\u00e1lez-Ram\u00edrez I, S\u00e1nchez-P\u00e9rez Y, Garc\u00eda-Cuellar CM. Deciphering the code between air pollution and disease: the effect of particulate matter on cancer hallmarks. Int J Mol Sci. 2019;21(1): 136.","DOI":"10.3390\/ijms21010136"},{"issue":"5","key":"656_CR13","first-page":"7506","volume":"15","author":"R Li","year":"2018","unstructured":"Li R, Zhou R, Zhang J. Function of PM2.5 in the pathogenesis of lung cancer and chronic airway inflammatory diseases. Oncol Lett. 2018;15(5):7506\u201314.","journal-title":"Oncol Lett"},{"key":"656_CR14","doi-asserted-by":"crossref","unstructured":"Pan J, Xue Y, Li S, Wang L, Mei J, Ni D et al. PM(2.5) induces the distant metastasis of lung adenocarcinoma via promoting the stem cell properties of cancer cells. Environmental pollution (Barking, Essex: 1987). 2022;296:118718.","DOI":"10.1016\/j.envpol.2021.118718"},{"key":"656_CR15","doi-asserted-by":"crossref","unstructured":"Yeh HL, Hsu SW, Chang YC, Chan TC, Tsou HC, Chang YC et al. Spatial analysis of ambient PM(2.5) exposure and bladder cancer mortality in Taiwan. Int J Environ Res Public Health. 2017;14(5): 508.","DOI":"10.3390\/ijerph14050508"},{"issue":"1","key":"656_CR16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euf.2016.11.008","volume":"4","author":"M Pedersen","year":"2018","unstructured":"Pedersen M, Stafoggia M, Weinmayr G, Andersen ZJ, Galassi C, Sommar J, et al. Is there an association between ambient air pollution and bladder cancer incidence? Analysis of 15 European cohorts. Eur Urol Focus. 2018;4(1):113\u201320.","journal-title":"Eur Urol Focus"},{"key":"656_CR17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.chemosphere.2018.10.183","volume":"216","author":"H Wang","year":"2019","unstructured":"Wang H, Gao Z, Ren J, Liu Y, Chang LT, Cheung K, et al. An urban-rural and sex differences in cancer incidence and mortality and the relationship with PM(2.5) exposure: an ecological study in the southeastern side of Hu line. Chemosphere. 2019;216:766\u201373.","journal-title":"Chemosphere"},{"key":"656_CR18","doi-asserted-by":"crossref","first-page":"109886","DOI":"10.1016\/j.cellsig.2020.109886","volume":"79","author":"G Wu","year":"2021","unstructured":"Wu G, Weng W, Xia P, Yan S, Zhong C, Xie L, et al. Wnt signalling pathway in bladder cancer. Cell Signal. 2021;79:109886.","journal-title":"Cell Signal"},{"key":"656_CR19","doi-asserted-by":"crossref","unstructured":"Abugomaa A, Elbadawy M, Yamawaki H, Usui T, Sasaki K. Emerging roles of cancer stem cells in bladder cancer Progression, Tumorigenesis, and resistance to chemotherapy: A potential therapeutic target for bladder cancer. Cells. 2020;9(1): 235.","DOI":"10.3390\/cells9010235"},{"issue":"1","key":"656_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-020-00307-z","volume":"21","author":"JM Bugter","year":"2021","unstructured":"Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21(1):5\u201321.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"656_CR21","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1038\/cddis.2011.7","volume":"2","author":"I Ahmad","year":"2011","unstructured":"Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, et al. Ras mutation cooperates with \u03b2-catenin activation to drive bladder tumourigenesis. Cell Death Dis. 2011;2(3):e124\u2013e.","journal-title":"Cell Death Dis"},{"issue":"2","key":"656_CR22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/1078-0432.CCR-05-1344","volume":"12","author":"S Urakami","year":"2006","unstructured":"Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt\/beta-catenin signaling pathway. Clin Cancer Research: Official J Am Association Cancer Res. 2006;12(2):383\u201391.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"656_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1746-1596-8-139","volume":"8","author":"R Malgor","year":"2013","unstructured":"Malgor R, Crouser S, Greco D, Brockett C, Coschigano K, Nakazawa M, et al. Correlation of Wnt5a expression with histopathological grade\/stage in urothelial carcinoma of the bladder. Diagn Pathol. 2013;8:139.","journal-title":"Diagn Pathol"},{"issue":"2","key":"656_CR24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1159\/000491911","volume":"48","author":"X Chen","year":"2018","unstructured":"Chen X, Jia C, Jia C, Jin X, Gu X. MicroRNA-374a inhibits aggressive tumor biological behavior in bladder carcinoma by suppressing Wnt\/\u03b2-Catenin signaling. Cell Physiol Biochem. 2018;48(2):815\u201326.","journal-title":"Cell Physiol Biochem"},{"issue":"6b","key":"656_CR25","first-page":"4571","volume":"20","author":"L Nakopoulou","year":"2000","unstructured":"Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P, et al. Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res. 2000;20(6b):4571\u20138.","journal-title":"Anticancer Res"},{"issue":"1","key":"656_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ijc.23917","volume":"124","author":"E Kastritis","year":"2009","unstructured":"Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, Kavantzas N, et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer. 2009;124(1):103\u20138.","journal-title":"Int J Cancer"},{"key":"656_CR27","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3389\/fphys.2019.01404","volume":"10","author":"Z Xu","year":"2019","unstructured":"Xu Z, Ding W, Deng X. PM(2.5), fine particulate matter: A novel player in the Epithelial-Mesenchymal transition? Front Physiol. 2019;10:1404.","journal-title":"Front Physiol"},{"issue":"2","key":"656_CR28","first-page":"1180","volume":"41","author":"H Xu","year":"2019","unstructured":"Xu H, Jiao X, Wu Y, Li S, Cao L, Dong L. Exosomes derived from PM2.5\u2013treated lung cancer cells promote the growth of lung cancer via the Wnt3a\/\u03b2\u2013catenin pathway. Oncol Rep. 2019;41(2):1180\u20138.","journal-title":"Oncol Rep"},{"issue":"2","key":"656_CR29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/onc.2010.399","volume":"30","author":"I Ahmad","year":"2011","unstructured":"Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, et al. \u03b2-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene. 2011;30(2):178\u201389.","journal-title":"Oncogene"},{"issue":"2","key":"656_CR30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrurol.2017.179","volume":"15","author":"KM Felsenstein","year":"2018","unstructured":"Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Reviews Urol. 2018;15(2):92\u2013111.","journal-title":"Nat Reviews Urol"},{"key":"656_CR31","doi-asserted-by":"crossref","unstructured":"Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers. Cancers (Basel). 2021;13(20): 5059.","DOI":"10.3390\/cancers13205059"},{"key":"656_CR32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.biopha.2016.12.022","volume":"86","author":"X Sun","year":"2017","unstructured":"Sun X, Deng Q, Liang Z, Liu Z, Geng H, Zhao L, et al. Cigarette smoke extract induces epithelial-mesenchymal transition of human bladder cancer T24 cells through activation of ERK1\/2 pathway. Biomed Pharmacother. 2017;86:457\u201365.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"656_CR33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-018-0049-y","volume":"2","author":"WJ Jeong","year":"2018","unstructured":"Jeong WJ, Ro EJ, Choi KY. Interaction between Wnt\/\u03b2-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of \u03b2-catenin and RAS by targeting the Wnt\/\u03b2-catenin pathway. NPJ Precis Oncol. 2018;2(1):5.","journal-title":"NPJ Precis Oncol"},{"issue":"Pt 2","key":"656_CR34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1242\/jcs.01601","volume":"118","author":"MS Yun","year":"2005","unstructured":"Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY. Both ERK and Wnt\/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci. 2005;118(Pt 2):313\u201322.","journal-title":"J Cell Sci"},{"issue":"219","key":"656_CR35","doi-asserted-by":"crossref","first-page":"ra30","DOI":"10.1126\/scisignal.2002242","volume":"5","author":"WJ Jeong","year":"2012","unstructured":"Jeong WJ, Yoon J, Park JC, Lee SH, Lee SH, Kaduwal S, et al. Ras stabilization through aberrant activation of Wnt\/\u03b2-catenin signaling promotes intestinal tumorigenesis. Sci Signal. 2012;5(219):ra30.","journal-title":"Sci Signal"},{"issue":"46","key":"656_CR36","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.0909409106","volume":"106","author":"V Jenei","year":"2009","unstructured":"Jenei V, Sherwood V, Howlin J, Linnskog R, S\u00e4fholm A, Axelsson L, et al. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A. 2009;106(46):19473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"656_CR37","doi-asserted-by":"crossref","first-page":"23246","DOI":"10.1074\/jbc.M112.372029","volume":"287","author":"ME Dodge","year":"2012","unstructured":"Dodge ME, Moon J, Tuladhar R, Lu J, Jacob LS, Zhang LS, et al. Diverse chemical scaffolds support direct Inhibition of the membrane-bound O-acyltransferase Porcupine. J Biol Chem. 2012;287(27):23246\u201354.","journal-title":"J Biol Chem"},{"issue":"9","key":"656_CR38","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/acs.jmedchem.8b00095","volume":"61","author":"B Garc\u00eda-Reyes","year":"2018","unstructured":"Garc\u00eda-Reyes B, Witt L, Jansen B, Karasu E, Gehring T, Leban J, et al. Discovery of inhibitor of Wnt production 2 (IWP-2) and related compounds as selective ATP-Competitive inhibitors of casein kinase 1 (CK1) \u03b4\/\u03b5. J Med Chem. 2018;61(9):4087\u2013102.","journal-title":"J Med Chem"},{"issue":"2","key":"656_CR39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nchembio.137","volume":"5","author":"B Chen","year":"2009","unstructured":"Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5(2):100\u20137.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"656_CR40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.celrep.2016.05.071","volume":"16","author":"SY Hwang","year":"2016","unstructured":"Hwang SY, Deng X, Byun S, Lee C, Lee SJ, Suh H, et al. Direct targeting of \u03b2-Catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt\/\u03b2-Catenin signaling. Cell Rep. 2016;16(1):28\u201336.","journal-title":"Cell Rep"},{"issue":"4","key":"656_CR41","first-page":"547","volume":"68","author":"S W\u0105troba","year":"2021","unstructured":"W\u0105troba S, Wi\u015bniowski T, Bryda J, Kurzepa J. The role of matrix metalloproteinases in pathogenesis of human bladder cancer. Acta Biochim Pol. 2021;68(4):547\u201355.","journal-title":"Acta Biochim Pol"},{"issue":"11","key":"656_CR42","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1074\/jbc.M114.612648","volume":"290","author":"JP Dijksterhuis","year":"2015","unstructured":"Dijksterhuis JP, Baljinnyam B, Stanger K, Sercan HO, Ji Y, Andres O, et al. Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem. 2015;290(11):6789\u201398.","journal-title":"J Biol Chem"},{"key":"656_CR43","doi-asserted-by":"crossref","first-page":"106654","DOI":"10.1016\/j.phrs.2023.106654","volume":"188","author":"Q Wu","year":"2023","unstructured":"Wu Q, Chen P, Li J, Lin Z, Zhang Q, Kwok HF. Inhibition of bladder cancer growth with Homoharringtonine by inactivating integrin \u03b15\/\u03b21-FAK\/Src axis: A novel strategy for drug application. Pharmacol Res. 2023;188:106654.","journal-title":"Pharmacol Res"},{"issue":"7","key":"656_CR44","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/cbic.202000626","volume":"22","author":"S Sani","year":"2021","unstructured":"Sani S, Messe M, Fuchs Q, Pierrevelcin M, Laquerriere P, Entz-Werle N, et al. Biological relevance of RGD-Integrin Subtype-Specific ligands in cancer. ChemBioChem. 2021;22(7):1151\u201360.","journal-title":"ChemBioChem"},{"issue":"1","key":"656_CR45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0048-9697(99)00471-4","volume":"247","author":"G Grimmer","year":"2000","unstructured":"Grimmer G, Dettbarn G, Seidel A, Jacob J. Detection of carcinogenic aromatic amines in the urine of non-smokers. Sci Total Environ. 2000;247(1):81\u201390.","journal-title":"Sci Total Environ"},{"issue":"1","key":"656_CR46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s13046-019-1380-z","volume":"38","author":"MY Li","year":"2019","unstructured":"Li MY, Liu LZ, Li W, Ng CSH, Liu Y, Kong AWY, et al. Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis. J Exp Clin Cancer Res. 2019;38(1):359.","journal-title":"J Exp Clin Cancer Res"},{"key":"656_CR47","doi-asserted-by":"crossref","unstructured":"Kim HB, Shim JY, Park B, Lee YJ. Long-Term exposure to air pollutants and cancer mortality: A Meta-Analysis of cohort studies. Int J Environ Res Public Health. 2018;15(11): 2608.","DOI":"10.3390\/ijerph15112608"},{"issue":"1","key":"656_CR48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","volume":"124","author":"NM Novikov","year":"2021","unstructured":"Novikov NM, Zolotaryova SY, Gautreau AM, Denisov EV. Mutational drivers of cancer cell migration and invasion. Br J Cancer. 2021;124(1):102\u201314.","journal-title":"Br J Cancer"},{"issue":"11","key":"656_CR49","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/tox.22437","volume":"32","author":"H Wei","year":"2017","unstructured":"Wei H, Liang F, Cheng W, Zhou R, Wu X, Feng Y, et al. The mechanisms for lung cancer risk of PM(2.5): induction of epithelial-mesenchymal transition and cancer stem cell properties in human non-small cell lung cancer cells. Environ Toxicol. 2017;32(11):2341\u201351.","journal-title":"Environ Toxicol"},{"issue":"12","key":"656_CR50","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1166\/jbn.2018.2645","volume":"14","author":"Z Chen","year":"2018","unstructured":"Chen Z, Ji N, Wang Z, Wu C, Sun Z, Li Y, et al. Fine particulate matter (PM(2.5)) promoted the invasion of lung cancer cells via an ARNT2\/PP2A\/STAT3\/MMP2 pathway. J Biomed Nanotechnol. 2018;14(12):2172\u201384.","journal-title":"J Biomed Nanotechnol"},{"issue":"5","key":"656_CR51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrurol.2011.44","volume":"8","author":"T Szarvas","year":"2011","unstructured":"Szarvas T, vom Dorp F, Erg\u00fcn S, R\u00fcbben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Reviews Urol. 2011;8(5):241\u201354.","journal-title":"Nat Reviews Urol"},{"issue":"6","key":"656_CR52","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/ar.24188","volume":"303","author":"R Roy","year":"2020","unstructured":"Roy R, Morad G, Jedinak A, Moses MA. Metalloproteinases and their roles in human cancer. Anat Rec (Hoboken). 2020;303(6):1557\u201372.","journal-title":"Anat Rec (Hoboken)"},{"issue":"5","key":"656_CR53","first-page":"1323","volume":"21","author":"MW Roomi","year":"2009","unstructured":"Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009;21(5):1323\u201333.","journal-title":"Oncol Rep"},{"issue":"1","key":"656_CR54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R. Wnt\/\u03b2-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci. 2024;81(1):79.","journal-title":"Cell Mol Life Sci"},{"issue":"23","key":"656_CR55","doi-asserted-by":"crossref","first-page":"18991","DOI":"10.1007\/s11356-017-9430-6","volume":"24","author":"X Hu","year":"2017","unstructured":"Hu X, Li Q, Shao S, Zeng Q, Jiang S, Wu Q, et al. Potential lung carcinogenicity induced by chronic exposure to PM2.5 in the rat. Environ Sci Pollut Res. 2017;24(23):18991\u20139000.","journal-title":"Environ Sci Pollut Res"},{"key":"656_CR56","doi-asserted-by":"crossref","unstructured":"Asem MS, Buechler S, Wates RB, Miller DL, Stack MS. Wnt5a signaling in cancer. Cancers (Basel). 2016;8(9): 79.","DOI":"10.3390\/cancers8090079"},{"issue":"18","key":"656_CR57","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1074\/jbc.RA118.001689","volume":"293","author":"X Huang","year":"2018","unstructured":"Huang X, Zhu H, Gao Z, Li J, Zhuang J, Dong Y, et al. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J Biol Chem. 2018;293(18):6693\u2013706.","journal-title":"J Biol Chem"},{"issue":"5","key":"656_CR58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5527\/wjn.v8.i5.83","volume":"8","author":"M Garg","year":"2019","unstructured":"Garg M, Maurya N. WNT\/\u03b2-catenin signaling in urothelial carcinoma of bladder. World J Nephrol. 2019;8(5):83\u201394.","journal-title":"World J Nephrol"},{"issue":"1","key":"656_CR59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O\u2019Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus Paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020;184(1):53\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"656_CR60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nm.4219","volume":"23","author":"Z Steinhart","year":"2017","unstructured":"Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med. 2017;23(1):60\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"656_CR61","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2019000757","volume":"4","author":"JH Lee","year":"2020","unstructured":"Lee JH, Faderl S, Pagel JM, Jung CW, Yoon SS, Pardanani AD, et al. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020;4(9):2032\u201343.","journal-title":"Blood Adv"},{"issue":"1","key":"656_CR62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13046-019-1261-5","volume":"38","author":"H Zhao","year":"2019","unstructured":"Zhao H, Zhao C, Li H, Zhang D, Liu G. E2A attenuates tumor-initiating capacity of colorectal cancer cells via the Wnt\/beta-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):276.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"656_CR63","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1158\/0008-5472.CAN-15-1519","volume":"76","author":"L Fang","year":"2016","unstructured":"Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI, et al. A Small-Molecule antagonist of the \u03b2-Catenin\/TCF4 interaction blocks the Self-Renewal of cancer stem cells and suppresses tumorigenesis. Cancer Res. 2016;76(4):891\u2013901.","journal-title":"Cancer Res"},{"issue":"1","key":"656_CR64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12943-018-0773-5","volume":"17","author":"T Sinnberg","year":"2018","unstructured":"Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, et al. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Mol Cancer. 2018;17(1):59.","journal-title":"Mol Cancer"},{"key":"656_CR65","doi-asserted-by":"crossref","unstructured":"Chen L, Chiang YC, Chan LS, Chau WY, Lung ML, Kahn M et al. The CBP\/\u03b2-Catenin Antagonist, ICG-001, inhibits tumor metastasis via blocking of the miR-134\/ITGB1 Axis-Mediated cell adhesion in nasopharyngeal carcinoma. Cancers (Basel). 2022;14(13): 3125.","DOI":"10.3390\/cancers14133125"},{"issue":"2","key":"656_CR66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","volume":"52","author":"YS Jung","year":"2020","unstructured":"Jung YS, Park JI. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex. Exp Mol Med. 2020;52(2):183\u201391.","journal-title":"Exp Mol Med"},{"issue":"10","key":"656_CR67","first-page":"Cd013774","volume":"10","author":"P Maisch","year":"2023","unstructured":"Maisch P, Hwang EC, Kim K, Narayan VM, Bakker C, Kunath F, et al. Immunotherapy for advanced or metastatic urothelial carcinoma. Cochrane Database Syst Rev. 2023;10(10):Cd013774.","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"656_CR68","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus Gemcitabine-Cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389.","journal-title":"N Engl J Med"},{"issue":"13","key":"656_CR69","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330.","journal-title":"N Engl J Med"},{"issue":"10","key":"656_CR70","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/0008-5472.CAN-19-3074","volume":"80","author":"L Ji","year":"2020","unstructured":"Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, et al. Blockade of \u03b2-Catenin-Induced CCL28 suppresses gastric cancer progression via Inhibition of Treg cell infiltration. Cancer Res. 2020;80(10):2004\u201316.","journal-title":"Cancer Res"},{"key":"656_CR71","doi-asserted-by":"crossref","first-page":"108921","DOI":"10.1016\/j.biopha.2019.108921","volume":"115","author":"J Xue","year":"2019","unstructured":"Xue J, Yu X, Xue L, Ge X, Zhao W, Peng W. Intrinsic \u03b2-catenin signaling suppresses CD8(+) T-cell infiltration in colorectal cancer. Biomed Pharmacother. 2019;115:108921.","journal-title":"Biomed Pharmacother"},{"key":"656_CR72","doi-asserted-by":"crossref","first-page":"102145","DOI":"10.1016\/j.tranon.2024.102145","volume":"50","author":"M Hashemi","year":"2024","unstructured":"Hashemi M, Rezaei M, Rezaeiaghdam H, Jamali B, Koohpar ZK, Tanha M, et al. Highlighting function of Wnt signalling in urological cancers: molecular interactions, therapeutic strategies, and (nano)strategies. Transl Oncol. 2024;50:102145.","journal-title":"Transl Oncol"},{"issue":"1","key":"656_CR73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"656_CR74","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Sampson C, Liu C, Piao H-l, Liu H-X. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell Communication Signal. 2023;21(1):266.","journal-title":"Cell Communication Signal"},{"issue":"6","key":"656_CR75","first-page":"1557","volume":"34","author":"B Kumar","year":"2009","unstructured":"Kumar B, Sinclair J, Khandrika L, Koul S, Wilson S, Koul HK. Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells. Int J Oncol. 2009;34(6):1557\u201364.","journal-title":"Int J Oncol"},{"key":"656_CR76","doi-asserted-by":"crossref","first-page":"108458","DOI":"10.1016\/j.pharmthera.2023.108458","volume":"247","author":"F Liu","year":"2023","unstructured":"Liu F, Wu Q, Dong Z, Liu K. Integrins in cancer: emerging mechanisms and therapeutic opportunities. Pharmacol Ther. 2023;247:108458.","journal-title":"Pharmacol Ther"},{"issue":"7492","key":"656_CR77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Comprehensive molecular characterization","year":"2014","unstructured":"Comprehensive molecular characterization. Of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322.","journal-title":"Nature"},{"issue":"10","key":"656_CR78","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1634\/theoncologist.2020-0292","volume":"25","author":"C Weekes","year":"2020","unstructured":"Weekes C, Lockhart A, LoRusso P, Murray E, Park E, Tagen M, et al. A phase Ib study to evaluate the MEK inhibitor Cobimetinib in combination with the ERK1\/2 inhibitor GDC-0994 in patients with advanced solid tumors. Oncologist. 2020;25(10):833\u2013e1438.","journal-title":"Oncologist"},{"key":"656_CR79","doi-asserted-by":"crossref","unstructured":"Kim J, Lee TS, Lee MH, Cho IR, Ryu JK, Kim YT et al. Pancreatic cancer treatment targeting the HGF\/c-MET pathway: the MEK inhibitor Trametinib. Cancers (Basel). 2024;16(5): 1056.","DOI":"10.3390\/cancers16051056"},{"issue":"1","key":"656_CR80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12890-024-03178-4","volume":"24","author":"M Zahmatyar","year":"2024","unstructured":"Zahmatyar M, Kharaz L, Abiri Jahromi N, Jahanian A, Shokri P, Nejadghaderi SA. The safety and efficacy of binimetinib for lung cancer: a systematic review. BMC Pulm Med. 2024;24(1):379.","journal-title":"BMC Pulm Med"},{"issue":"15","key":"656_CR81","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"656_CR82","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-Class ERK1\/2 inhibitor Ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I Dose-Escalation and expansion study. Cancer Discov. 2018;8(2):184\u201395.","journal-title":"Cancer Discov"},{"issue":"6","key":"656_CR83","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-19-2574","volume":"26","author":"A Varga","year":"2020","unstructured":"Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, et al. A First-in-Human phase I study to evaluate the ERK1\/2 inhibitor GDC-0994 in patients with advanced solid tumors. Clin Cancer Research: Official J Am Association Cancer Res. 2020;26(6):1229\u201336.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"656_CR84","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.MCT-19-0183","volume":"19","author":"SV Bhagwat","year":"2020","unstructured":"Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, et al. ERK inhibitor LY3214996 targets ERK Pathway-Driven cancers: A therapeutic approach toward precision medicine. Mol Cancer Ther. 2020;19(2):325\u201336.","journal-title":"Mol Cancer Ther"},{"key":"656_CR85","doi-asserted-by":"crossref","unstructured":"Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC et al. Development of MK-8353, an orally administered ERK1\/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018;3(4): e92352.","DOI":"10.1172\/jci.insight.92352"},{"issue":"1","key":"656_CR86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13046-019-1226-8","volume":"38","author":"Z Yan","year":"2019","unstructured":"Yan Z, Ohuchida K, Fei S, Zheng B, Guan W, Feng H, et al. Inhibition of ERK1\/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. J Exp Clin Cancer Res. 2019;38(1):221.","journal-title":"J Exp Clin Cancer Res"},{"key":"656_CR87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","volume":"211","author":"TJ Ettrich","year":"2018","unstructured":"Ettrich TJ, Seufferlein T, Regorafenib. Recent Results Cancer Res. 2018;211:45\u201356.","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"656_CR88","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/tox.22734","volume":"34","author":"CH Chiang","year":"2019","unstructured":"Chiang CH, Chung JG, Hsu FT. Regorefenib induces extrinsic\/intrinsic apoptosis and inhibits MAPK\/NF-\u03baB-modulated tumor progression in bladder cancer in vitro and in vivo. Environ Toxicol. 2019;34(6):679\u201388.","journal-title":"Environ Toxicol"},{"key":"656_CR89","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y et al. Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021;39(10):1375-87.e6.","DOI":"10.1016\/j.ccell.2021.07.023"},{"issue":"206","key":"656_CR90","first-page":"ra3","volume":"5","author":"TL Biechele","year":"2012","unstructured":"Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, et al. Wnt\/\u03b2-catenin signaling and AXIN1 regulate apoptosis triggered by Inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal. 2012;5(206):ra3.","journal-title":"Sci Signal"},{"issue":"6","key":"656_CR91","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-11-3222","volume":"72","author":"D Horst","year":"2012","unstructured":"Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012;72(6):1547\u201356.","journal-title":"Cancer Res"}],"container-title":["Particle and Fibre Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12989-025-00656-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12989-025-00656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12989-025-00656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:33:39Z","timestamp":1769092419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12989-025-00656-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1186\/s12989-025-00656-3","relation":{},"ISSN":["1743-8977"],"issn-type":[{"value":"1743-8977","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants nor animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}